首页> 外文期刊>Bioconjugate Chemistry >First Self-Adjuvant Multicomponent Potential Vaccine Candidates by Tethering of Four or Eight MUC1 Antigenic Immunodominant PDTRP Units on a Calixarene Platform: Synthesis and Biological Evaluation
【24h】

First Self-Adjuvant Multicomponent Potential Vaccine Candidates by Tethering of Four or Eight MUC1 Antigenic Immunodominant PDTRP Units on a Calixarene Platform: Synthesis and Biological Evaluation

机译:在杯形芳烃平台上通过束缚四个或八个MUC1抗原免疫敏化PDTRP单位的第一个自佐剂多组分潜在疫苗候选者:合成和生物学评估

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

MUC1 protein overexpressed in human epithelial carcinoma is a target in development of novel anticancer vaccines. Multiple units of immunodominant B-cell epitope PDTRP MUC1 core sequence were conjugated to calix[4,8]arene platforms containing TLR2 ligand, to produce two novel anticancer self-adjuvant vaccine candidates. The immunogenicity of the synthetic constructs was investigated by immunization of mice in vivo. ELISA assay evidenced that the vaccine candidates stimulate anti MUC1 IgG antibody production (major for the octavalent construct) and no additive effect but a multivalency effect was observed when compared to an analogous monovalent. Octa- and tetravalent constructs lacking in PDTRP peptide moieties did not show anti MUC1 IgG antibody production in mice. The antibodies induced by the synthesized constructs are able to recognize the MUCl structures present on MCF7 tumor cells. The results display that calixarenes are convenient platforms for building multicomponent self-adjuvant vaccine constructs promising as immunotherapeutic anticancer agents.
机译:在人类上皮癌中过表达的MUC1蛋白是新型抗癌疫苗开发的目标。将多个单位的免疫优势B细胞抗原决定簇PDTRP MUC1核心序列缀合到含有TLR2配体的杯[4,8] arene平台上,以产生两种新型的抗癌自佐剂疫苗候选物。通过体内免疫小鼠研究了合成构建体的免疫原性。 ELISA测定法证明,候选疫苗可刺激抗MUC1 IgG抗体的产生(主要针对八价构建体),无累加作用,但与类似的单价相比,可观察到多价作用。缺少PDTRP肽部分的八价和四价构建体在小鼠中未显示出抗MUC1 IgG抗体的产生。由合成的构建体诱导的抗体能够识别MCF7肿瘤细胞上存在的MUC1结构。结果表明,杯芳烃是构建有希望作为免疫治疗抗癌剂的多组分自佐剂疫苗构建体的便利平台。

著录项

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号